St. Jude Announces European Market Launch of QuickSite

St. Jude has announced the European market launch of the QuickSite 1056T bipolar left-heart pacing lead, the world's first cardiac resynchronization therapy lead to combine bipolar pacing capability with a composite body for superior handling and a unique S-shaped distal tip for outstanding stability.

Specifically designed for placement in the coronary sinus, St. Jude's QuickSite 1056T bipolar lead enables left-ventricular pacing in cardiac resynchronization therapy applications. At 5.5 French, the lead body is as small in diameter as the previously available QuickSite 1056K unipolar lead.

The lead has been submitted to the FDA for approval in the U.S.